ANI Pharmaceuticals (NASDAQ: BPAX) and OncoMed Pharmaceuticals (NASDAQ:OMED) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, risk, earnings and dividends.

Institutional & Insider Ownership

51.7% of OncoMed Pharmaceuticals shares are owned by institutional investors. 32.8% of OncoMed Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Earnings & Valuation

This table compares ANI Pharmaceuticals and OncoMed Pharmaceuticals’ top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
ANI Pharmaceuticals N/A N/A N/A N/A N/A
OncoMed Pharmaceuticals $24.55 million 6.50 -$82.33 million ($2.38) -1.78

ANI Pharmaceuticals has higher revenue, but lower earnings than OncoMed Pharmaceuticals.


This table compares ANI Pharmaceuticals and OncoMed Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
ANI Pharmaceuticals 5.99% 6.12% 3.00%
OncoMed Pharmaceuticals -350.49% N/A -49.95%

Analyst Ratings

This is a breakdown of recent ratings and price targets for ANI Pharmaceuticals and OncoMed Pharmaceuticals, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ANI Pharmaceuticals 0 0 0 0 N/A
OncoMed Pharmaceuticals 0 6 2 0 2.25

OncoMed Pharmaceuticals has a consensus target price of $7.71, indicating a potential upside of 81.94%. Given OncoMed Pharmaceuticals’ higher possible upside, analysts clearly believe OncoMed Pharmaceuticals is more favorable than ANI Pharmaceuticals.


OncoMed Pharmaceuticals beats ANI Pharmaceuticals on 5 of the 8 factors compared between the two stocks.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc. is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company focuses on areas, including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations. It also performs contract manufacturing for other pharmaceutical companies. Its products include both branded and generic pharmaceuticals. Its generic products include Erythromycin Ethylsuccinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Flecainide, Fluvoxamine, Hydrocortisone Enema, Methazolamide, Metoclopramide Syrup Nilutamide, Nimodipine, Opium Tincture, Oxycodone Capsules, Oxycodone Oral Solution, Propafenone and Vancomycin. Its branded products include Cortenema, Inderal LA, Lithobid, Reglan and Vancocin. Its pharmaceutical manufacturing facilities are located in Baudette, Minnesota.

About OncoMed Pharmaceuticals

OncoMed Pharmaceuticals, Inc. (OncoMed) is a clinical-stage biopharmaceutical company. The Company focuses on discovering and developing therapeutics that address the fundamental biology driving cancer’s growth, resistance, recurrence and metastasis. The Company’s therapeutic candidates and preclinical programs include Demcizumab (Anti-DLL4, OMP-21M18), Tarextumab (Anti-Notch2/3, OMP-59R5), Vantictumab (anti-Fzd7, OMP-18R5), Ipafricept (Fzd8-Fc, OMP-54F28), Brontictuzumab (Anti-Notch1, OMP-52M51), Navicixizumab (Anti-DLL4/VEGF Bispecific, OMP-305B83), Anti-RSPO3 (OMP-131R10), Anti-TIGIT (OMP-313M32) and GITRL-Fc trimer (OMP-336B11). Demcizumab is a humanized monoclonal antibody that inhibits Delta-like Ligand 4 (DLL4) in the Notch signaling pathway. Tarextumab is a human monoclonal antibody that binds to both the Notch2 and Notch3 receptors.

Receive News & Stock Ratings for ANI Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals Inc and related stocks with our FREE daily email newsletter.